| Comprehensive Screening Panel | Unspecific | ICECP 170 Panel ↗ | A comprehensive cancer cell panel designed to evaluate drug efficacy across 170 diverse cancer cell lines representing a broad range of tumor types and genetic backgrounds. |
| ICECP 30 Panel | A focused cancer cell panel consisting of 30 well-characterized cell lines. |
| Cell Panel-Based CDX Models | In vivo systems where human cancer cell lines are implanted into immunocompromised mice to study tumor growth and therapeutic response. |
| Target-Specific Panel | RAS (2D and 3D) | Pan KRAS 20 Cell Panel | 20+ RAS-related panels, constantly updated.
Composition: 20 or 40 fixed cell lines across 5–15 cancer types.
Mutations: KRAS G12C, G12V, G12D, and NRAS mutations.
Assay Formats: 2D/3D CellTiter-Glo assays.
Assay Duration: 5–7 days.
Plate Formats: 384-well or 96-well.
Turnaround Time: 2–3 weeks.
Special Panels: RAS-resistant and Ba/F3 cell-line options. |
| Pan KRAS 40 Cell Panel |
| KRAS G12D 20 Cell Panel |
| KRAS G12D 40 Cell Panel |
| KRAS G12C 20 Cell Panel |
| KRAS G12C 40 Cell Panel |
| KRAS G12V 20 Cell Panel |
| KRAS G12V 40 Cell Panel |
| Pan NRAS 20 Cell Panel |
| Pan NRAS 40 Cell Panel |
| Customized RAS Cell Panel | Flexible selection for evaluating inhibitor efficacy against HRAS, KRAS, and NRAS mutations and validating drug selectivity. |
| DNA Damage Response | DDR 30 2D Cell Panel | 30 or 65 cell lines for DDR-related targets.
Study Design: Monotherapy and combination therapy using engineered and drug-resistant cells.
Mutation Information: DDR genes including BRCA and TP53.
Assay Duration: 3–7 days or 7–10 days.
Plate Format: 384-well or 96-well.
Turnaround Time: 3–4 weeks. |
| DDR 65 2D Cell Panel |
| DDR Customized 2D Cell Panel | Flexible cell-line selection. |
| PARP1/2 | PARP 30 2D Cell Panel | 30 or 50 cell lines targeting PARP1/2.
Study Design: Monotherapy and combination therapy using engineered and drug-resistant cells.
Mutation Information: PARP1/2-related genes, including BRCA status.
Assay Duration: Approximately 7 days.
Turnaround Time: 2–3 weeks. |
| PARP 50 2D Cell Panel |
| BRCA-Mutated 2D Cell Panel | Customized PARP1/2 cell panel. |
| WRN | WRN 30 2D Cell Panel | 30 or 50 cell lines targeting WRN; up to 10% cell-line changes allowed with no price increase.
Cell Types: MSI, MSS, and MSI-high tumor cells, including WRN-resistant cell lines.
Assay Duration: 5–7 days.
Turnaround Time: 4–5 weeks. |
| WRN 50 2D Cell Panel |
| WRN Customized 2D Cell Panel | Flexible selection from 96 tumor cells with MSI, MSS, and MSI-high status, with DDR-gene mutation information. |
| Cancer-Specific Panel | Custom Breast Cancer Cell Panel | Selection from 50+ cell lines, including luminal A, luminal B, HER2-positive, and TNBC subtypes. |
| Custom Colorectal Cancer Cell Panel | Selection from 40+ cell lines. |
| Novel Molecule Panel | HER2 ADC Panel | 65 cell lines: 53 tumor cell lines plus 12 Ba/F3 cell lines across 10 cancer types. Includes HER2-positive and HER2-negative cell lines. In vitro bystander-effect panels and in vivo bystander-effect evaluation using mixed Ag+ cancer cells and Ag--Luc cells are available. |
